NOVARTIS PHARM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVARTIS PHARM, and what generic alternatives to NOVARTIS PHARM drugs are available?
NOVARTIS PHARM has five approved drugs.
There are fourteen US patents protecting NOVARTIS PHARM drugs.
There are three hundred and fifty-two patent family members on NOVARTIS PHARM drugs in fifty-four countries and ninety-four supplementary protection certificates in seventeen countries.
Summary for NOVARTIS PHARM
International Patents: | 352 |
US Patents: | 14 |
Tradenames: | 5 |
Ingredients: | 5 |
NDAs: | 5 |
Patent Litigation for NOVARTIS PHARM: | See patent lawsuits for NOVARTIS PHARM |
Drugs and US Patents for NOVARTIS PHARM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharm | AFINITOR DISPERZ | everolimus | TABLET, FOR SUSPENSION;ORAL | 203985-002 | Aug 29, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | RX | Yes | No | 8,101,659*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | RX | Yes | No | 7,468,390*PED | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-002 | May 6, 2020 | RX | Yes | Yes | 8,901,123 | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis Pharms | FEMARA | letrozole | TABLET;ORAL | 020726-001 | Jul 25, 1997 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NOVARTIS PHARM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis Pharm | AFINITOR DISPERZ | everolimus | TABLET, FOR SUSPENSION;ORAL | 203985-003 | Aug 29, 2012 | 6,004,973*PED | ⤷ Sign Up |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | 6,596,750 | ⤷ Sign Up |
Novartis Pharm | AFINITOR DISPERZ | everolimus | TABLET, FOR SUSPENSION;ORAL | 203985-001 | Aug 29, 2012 | 8,778,962*PED | ⤷ Sign Up |
Novartis Pharm | AFINITOR DISPERZ | everolimus | TABLET, FOR SUSPENSION;ORAL | 203985-002 | Aug 29, 2012 | 5,665,772*PED | ⤷ Sign Up |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | 6,465,504 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS PHARM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
➤ Subscribe | Tablets for Oral Suspension | 2 mg, 3 mg and 5 mg | ➤ Subscribe | 2016-12-30 |
➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
International Patents for NOVARTIS PHARM Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Serbia | 56890 | ⤷ Sign Up |
Cyprus | 1126036 | ⤷ Sign Up |
Guatemala | 200700055 | ⤷ Sign Up |
China | 102702119 | ⤷ Sign Up |
Australia | 2015293539 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NOVARTIS PHARM Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3342411 | 122020000008 | Germany | ⤷ Sign Up | PRODUCT NAME: EVEROLIMUS; REGISTRATION NO/DATE: EU/1/09/538/001-008 20110824 |
0236940 | 97C0053 | Belgium | ⤷ Sign Up | PRODUCT NAME: LETROZOLE; NAT. REGISTRATION NO/DATE: 206 IS 241 F 3 19970616; FIRST REGISTRATION: FR 341 474.2 1996072 |
2269603 | 122015000094 | Germany | ⤷ Sign Up | PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001 20120723 |
3172209 | 301208 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CAPMATINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/22/1650 20220621 |
2269603 | 300769 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EVEROLIMUS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/001, 003, 004 EN 006-010 (C(2012)5347) 20120725 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.